20304-86-3

Basic information

• Product Name: 5-METHYLBENZOFURAZAN
• Synonyms: 5-METHYLBENZOFURAZAN;5-METHYL-2,1,3-BENZOXADIAZOLE;BUTTPARK 29\04-28;5-METHYLBENZOFURAZAN 97%;5-Methylbenzfurazan;5-Methyl-2,1,3-benzoxadizole
• CAS NO: 20304-86-3
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Mol File: 20304-86-3.mol

Chemical Properties

• Melting Point: 33-35°C
• Boiling Point: 209.2°C at 760 mmHg
• Flash Point: 82°C
• Appearance: /
• Density: 1.229g/cm³
• Vapor Pressure: 0.297mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: 5-METHYLBENZOFURAZAN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYLBENZOFURAZAN(20304-86-3)
• EPA Substance Registry System: 5-METHYLBENZOFURAZAN(20304-86-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 20304-86-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research and Development:
5-Methylbenzofurazan is used as a reagent in various chemical reactions due to its oxidative properties. It aids in the synthesis of new compounds and contributes to the advancement of chemical research.
Used in Industrial Applications:
In the industrial sector, 5-Methylbenzofurazan is utilized for its oxidative characteristics, which can enhance the efficiency of certain chemical processes and improve the quality of end products.
Safety Precautions:
Due to its potential to cause skin and eye burns in the presence of moisture, 5-Methylbenzofurazan should be handled with care. Protective clothing and eye protection are essential when working with this chemical to minimize the risk of injury.

InChI:InChI=1/C7H6N2O/c1-5-2-3-6-7(4-5)9-10-8-6/h2-4H,1H3

Upstream product

• 612-45-3 4-methyl-2-nitroacetanilide 
• 19164-41-1 5-methylbenzofuroxan 
• 98549-95-2 4-methyl-1,2-dinitroso-benzene 
• 40468-66-4 (4-methyl-2-nitro-phenyl)-(1,2,5-triphenyl-1H-1λ⁵-phosphol-1-ylidene)-amine 
• 2617-79-0 N-(4-chlorophenyl)formamide 
• 90824-02-5 C₇H₅ClNO^(1-)*K⁽¹⁺⁾ 
• 53178-71-5 4-methylcyclohexa-3,5-diene-1,2-dione dioxime 
• 20615-75-2 4-azido-3-nitro-toluene 
• 89-62-3 4-methyl-2-nitroaniline 
• 3524-05-8 6-methylbenzofuroxan 
• 1073355-14-2 5?(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c][1,2,5]oxadiazole 
• 74-88-4 methyl iodide 
• 54948-54-8 5-methyl-2-nitroazidobenzene 

Downstream Products

• 32863-31-3 5-(bromomethyl)benzofurazan 
• 16322-21-7 5-Methyl-4-nitro-benzofurazan 
• 54286-59-8 5-Methylbenzofurazan-4-carbonitril 
• 32863-33-5 5-formylbenzofurazan 
• 6344-72-5 6-methylquinoxaline 
• 1297593-67-9 C₁₇H₁₄N₂O₃ 
• 480441-88-1 2-benzenesulfonyl-3,6-dimethyl-quinoxaline 1,4-dioxide 
• 480441-68-7 3,6-dimethyl-2-phenylsulfanyl-quinoxaline 1,4-dioxide 

Relevant articles and documents

A Common, Facile and Eco-Friendly Method for the Reduction of Nitroarenes, Selective Reduction of Poly-Nitroarenes and Deoxygenation of N-Oxide Containing Heteroarenes Using Elemental Sulfur

A transition metal-free, environment-friendly and practical protocol was developed either for the reduction of nitroarenes or for the deoxygenation of N-oxide containing heteroarenes. The reaction proceeded with the use of a non-toxic and cheap feedstock as elemental sulfur in aqueous methanol under relatively mild conditions. Green chemistry credentials were widely favorable compared to traditional and industrial protocols with good E-factors and a low production of waste. The strategy allowed the efficient reduction of a large variety of substituted-nitroarenes including various o-nitroanilines as well as selective reduction of various poly-nitroarenes in excellent yields with a broad substrate scope. The protocol was successfully extended to the deoxygenation of some N-oxide containing heteroarenes, like benzofuroxans, phenazine N,N'-dioxides, pyridine N-oxides, 2H-indazole N1-oxides, quinoxaline N1,N4-dioxides and benzo[d]imidazole N1,N3-dioxides. A gram-scale example for the synthesis of luminol, in green conditions, was reported. A solid mechanism of reaction was proposed from experimental evidences.

Palladium-Catalyzed Methylation of Aryl, Heteroaryl, and Vinyl Boronate Esters

A method for the direct methylation of aryl, heteroaryl, and vinyl boronate esters is reported, involving the reaction of iodomethane with aryl-, heteroaryl-, and vinylboronate esters catalyzed by palladium and PtBu2Me. This transformation occurs with a remarkably broad scope and is suitable for late-stage derivatization of biologically active compounds via the boronate esters. The unique capabilities of this method are demonstrated by combining carbon-boron bond-forming reactions with palladium-catalyzed methylation in a tandem transformation.

Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine

Nitrobenzylthioinosine (NBTI, 1) was systematically modified by attachment of substituents at positions C6 and N9, and also by substitution of N1 with C. These modifications were chosen to reduce the polarity of the new compounds. Incorporation of the nitro functionality into a benzoxadiazole ring system was considered first. These new nucleosides showed high affinity (1.5-10 nM) towards the nucleoside transport protein as present on human erythrocyte ghosts. Next, modification of this benzoxadiazole ring system with C, S and O in different positions produced a number of less polar nucleosides with affinity in the higher nanomolar range. Modification of N9 was achieved with different alkyl and alcohol substituents. An n-butyl substituent proved best, although all variations yielded substantial decreases in affinity. Replacement of N1 by a carbon atom in combination with a 2-Cl substituent also resulted in a relatively potent NBTI derivative (47 nM).

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

New analogs of nitrobenzylthioinosine

This invention relates to new analogs or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new analog of nitrobenzylthioinosine.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Creceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Creceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

5-(HETEROCYCLIC ALKYL)-6-ARYL-DIHYDROPYRIMIDINES

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1C receptors and which have the structure: STR1 wherein A is aryl; R 1, R 2 and R. sub.3 are alkyl or heteroalkyl; R 4 is heterocyclic alkyl; and X is S, O or NR 3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human α 1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.

Vergleichende Untersuchungen zur Arylaminierung von Benzofuroxan-Derivaten

The amination of benzofuroxan 2a and monosubstituted benzofuroxans 2b-e with alkali metal salts of formanilides 1 and sodium acetanilides 6 is described.Thus, the reaction of 2a with 6a-d gives the benzotriazole 1-oxides 3a-d.The benzofuroxans 2b and 2c react with sodium formanilides to give the isomeric mixtures 3f/3g and 3h/3i.Potassium 4-nitroformanilide reduces 2a furnishing benzofurazan 7.Nitrosubstituted benzofuroxans such as 2d and 2e undergo a carbocyclic amination leading to the benzofurazans 8 and 9.